The ginsenoside Rg1 prevents transverse aortic constriction-induced left ventricular hypertrophy and cardiac dysfunction by inhibiting fibrosis and enhancing angiogenesis

Journal of Cardiovascular Pharmacology

Volumn 62, Issue 1, 2013, Pages 50-57

  Zhang, Yao Jun ^a   Zhang, Xin Lei ^a   Li, Ming Hui ^a   Iqbal, Javaid ^b   Bourantas, Christos V ^c   Li, Jing Jing ^a   Su, Xing Yu ^a   Muramatsu, Takashi ^c   Tian, Nai Liang ^a   Chen, Shao Liang ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

angiogenesis; ginsenoside Rg1; hypoxia inducible factor 1; left ventricular hypertrophy; VEGF

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; GINSENOSIDE RG 1; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROCOLLAGEN; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HISTOPATHOLOGY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOTTING, WESTERN; CONSTRICTION, PATHOLOGIC; ENZYME ACTIVATION; FIBROSIS; GINSENOSIDES; HYPERTROPHY, LEFT VENTRICULAR; HYPOXIA-INDUCIBLE FACTOR 1; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; ONCOGENE PROTEIN V-AKT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PARAFFIN EMBEDDING; PROCOLLAGEN; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84880543015     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31828f8d45     Document Type: Article

References (32)

1. Shimbo D, Muntner P, Mann D, et al. Association of left ventricular hypertrophy with incident hypertension: the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2011;173:898-905.
2. Rosei EA. Assessment of preclinical target organ damage in hypertension: left ventricular hypertrophy. J Hypertens. 2002;20:156-158.
3. Cuspidi C, Negri F, Sala C, et al. Masked hypertension and echocardiographic left ventricular hypertrophy: an updated overview. Blood Press Monit. 2012;17:8-13.
4. Puri PL, Natoli G, Avantaggiati ML, et al. The molecular basis of myocardial hypertrophy. Ann Ital Med Int. 1994;9:160-165.
5. Ritter O, Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med. 2003;9:313-321.
6. Lips DJ, deWindt LJ, van KDJ, et al. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur Heart J. 2003;24:883-896.
7. Shu C, Chen C, Zhang DP, et al. Gastrodin protects against cardiac hypertrophy and fibrosis. Mol Cell Biochem. 2012;359:9-16.
8. Zhou H, Bian ZY, Zong J, et al. Stem cell antigen 1 protects against cardiac hypertrophy and fibrosis after pressure overload. Hypertension. 2012;60:802-809.
9. Sun B, Huo R, Sheng Y, et al. Bone morphogenetic protein-4 mediates cardiac hypertrophy, apoptosis, and fibrosis in experimentally pathological cardiac hypertrophy. Hypertension. 2013;61:352-360.
10. Albrecht-Schgoer K, Schgoer W, Holfeld J, et al. The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation. 2012;126:2491-2501.
11. Maureira P, Marie PY, Yu F, et al. Repairing chronic myocardial infarction with autologous mesenchymal stem cells engineered tissue in rat promotes angiogenesis and limits ventricular remodeling. J Biomed Sci. 2012;19:93.
12. Higashikuni Y, Sainz J, Nakamura K, et al. The ATP-binding cassette transporter ABCG2 protects against pressure overload-induced cardiac hypertrophy and heart failure by promoting angiogenesis and antioxidant response. Arterioscler Thromb Vasc Biol. 2012;32:654-661.
13. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol. 2009; 7:293-302.
14. Chen X. Cardiovascular protection by ginsenosides and their nitric oxide releasing action. Clin Exp Pharmacol Physiol. 1996;23: 728-732.
15. Xia R, Zhao B, Wu Y, et al. Ginsenoside Rb1 preconditioning enhances eNOS expression and attenuates myocardial ischemia/reperfusion injury in diabetic rats. J Biomed Biotechnol. 2011;2011:767930.
16. Cheung LW, Leung KW, Wong CK, et al. Ginsenoside-Rg1 induces angiogenesis via non-genomic crosstalk of glucocorticoid receptor and fibroblast growth factor receptor-1. Cardiovasc Res. 2011;89: 419-425.
17. Yin H, Liu Z, Li F, et al. Ginsenoside-Rg1 enhances angiogenesis and ameliorates ventricular remodeling in a rat model of myocardial infarction. J Mol Med (Berl). 2011;89:363-375.
18. Deng J, Lv XT, Wu Q, et al. Ginsenoside Rg(1) inhibits rat left ventricular hypertrophy induced by abdominal aorta coarctation: involvement of calcineurin and mitogen-activated protein kinase signalings. Eur J Pharmacol. 2009;608:42-47.
19. Deng J, Wang YW, Chen WM, et al. Role of nitric oxide in ginsenoside Rg(1)-induced protection against left ventricular hypertrophy produced by abdominal aorta coarctation in rats. Biol Pharm Bull. 2010;33:631-635.
20. den Bosch BJv, Lindsey PJ, van den Burg CM, et al. Early and transient gene expression changes in pressure overload-induced cardiac hypertrophy in mice. Genomics. 2006;88:480-488.
21. Zhu Y, Li T, Song J, et al. The TIR/BB-loop mimetic AS-1 prevents cardiac hypertrophy by inhibiting IL-1R-mediated MyD88-dependent signaling. Basic Res Cardiol. 2011;106:787-799.
22. Shiojima I, Sato K, Izumiya Y, et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest. 2005;115:2108-2118.
23. Karch R, Neumann F, Ullrich R, et al. The spatial pattern of coronary capillaries in patients with dilated, ischemic, or inflammatory cardiomyopathy. Cardiovasc Pathol. 2005;14:135-144.
24. Feng W, Ye F, Xue W, et al. Copper regulation of hypoxia-inducible factor-1 activity. Mol Pharmacol. 2009;75:174-182.
25. Leung KW, Ng HM, Tang MK, et al. Ginsenoside-Rg1 mediates a hypoxiaindependent upregulation of hypoxia-inducible factor-1alpha to promote angiogenesis. Angiogenesis. 2011;14:515-522.
26. Zou Y, Li J, Ma H, et al. Heat shock transcription factor 1 protects heart after pressure overload through promoting myocardial angiogenesis in male mice. J Mol Cell Cardiol. 2011;51:821-829.
27. Kazakov A, Muller P, Jagoda P, et al. Endothelial nitric oxide synthase of the bone marrow regulates myocardial hypertrophy, fibrosis, and angiogenesis. Cardiovasc Res. 2012;93:397-405.
28. Touyz RM, He G, El MM, et al. p38 Map kinase regulates vascular smooth muscle cell collagen synthesis by angiotensin II in SHR but not in WKY. Hypertension. 2001;37:574-580.
29. Martos R, Baugh J, Ledwidge M, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888-895.
30. Zhang ZL, Fan Y, Liu ML. Ginsenoside Rg1 inhibits autophagy in H9c2 cardiomyocytes exposed to hypoxia/reoxygenation. Mol Cell Biochem. 2012;365:243-250.
31. Zong Y, Ai QL, Zhong LM, et al. Ginsenoside Rg1 attenuates lipopolysaccharide-induced inflammatory responses via the phospholipase C-gamma1 signaling pathway in murine BV-2 microglial cells. Curr Med Chem. 2012;19:770-779.
32. Deng M, Sui XQ, Zhu SB, et al. Clinical observation on the treatment of atrial fibrillation with amiodarone combined with Shenmai Injection. Chin J Integr Med. 2010;16:453-456. of Jiangsu Province